NewsBenzingaElicio Therapeutics présente des données de son essai de phase 2 AMPLIFY-7P sur le camupepimut au congrès 2026 de la Société européenne d’oncologie médicale. Elicio Therapeutics présente des données de son essai de phase 2 AMPLIFY-7P sur le camupepimut au congrès 2026 de la Société européenne d’oncologie médicale. Benzinga 2026.10.23 13:01 (GMT+0) Open on Benzinga Other news Here's How Much $1000 Invested In Analog Devices 20 Years Ago Would Be Worth Today RPC Says Richard A. Hubbell To Retire As Executive Chairman And Director Effective Dec 31, 2026 Neocloud Stocks Catch a Bid After Nvidia Q3 Beat NVIDIA Interim CEO Says Co.'s Q4 Sales Growth To Be Driven By AI Demand, Vera Rubin Rollout NVIDIA Interim CEO Says Co. Remains On Track To Launch Vera Rubin Ultra Next Year And Feynman In 2028 ReAlpha Tech Corp Q3 EPS $(0.60) Misses $(0.50) Estimate, Sales $1.604M Miss $5.644M Estimate
NVIDIA Interim CEO Says Co. Remains On Track To Launch Vera Rubin Ultra Next Year And Feynman In 2028